Wedbush Analysts Decrease Earnings Estimates for Pharvaris

Pharvaris (NASDAQ:PHVS - Free Report) - Research analysts at Wedbush dropped their Q1 2025 EPS estimates for Pharvaris in a research note issued to investors on Monday, April 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.92) per share for the quarter, down from their prior forecast of ($0.77). The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Pharvaris' Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.70) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($2.46) EPS and FY2028 earnings at $0.43 EPS.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Monday, April 7th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06.

Separately, JMP Securities increased their price objective on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research report on Friday, January 31st.

Pharvaris Trading Up 5.4 %

PHVS stock traded up $0.68 during trading hours on Thursday, hitting $13.30. 14,342 shares of the stock traded hands, compared to its average volume of 71,224. Pharvaris has a one year low of $11.51 and a one year high of $25.50. The company has a market cap of $695.46 million, a P/E ratio of -4.75 and a beta of -2.84. The stock has a 50-day simple moving average of $15.45 and a 200 day simple moving average of $18.32.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Pharvaris by 30.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock worth $1,222,000 after purchasing an additional 14,838 shares during the period. Woodline Partners LP bought a new stake in shares of Pharvaris during the 4th quarter worth $853,000. Soleus Capital Management L.P. grew its stake in Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock valued at $15,617,000 after buying an additional 216,483 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Pharvaris in the 4th quarter valued at $152,000. Finally, Octagon Capital Advisors LP raised its holdings in Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock worth $14,914,000 after acquiring an additional 157,530 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.